Shield Presents Positive Results for Feraccru®/Accrufer™ (Ferric Maltol) in AEGIS-H2H phase 3b non-inferiority study at UEG Week 2019

22 Oct 2019

Shield Therapeutics plc, announces that results from its multicentre phase 3b, open-label randomised controlled trial will be presented at the 27th United European Gastroenterology Week (UEG). Headline data were previously announced in March 2019. For further details click here.

Back to news